ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag drug discovery evolution microbiology

Different colored cartoon viruses entering holes in a cartoon of a human brain.
A Journey Into the Brain
Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.
Tag, You're It
Carina Storrs | Feb 1, 2014 | 7 min read
A guide to DNA-encoded libraries for drug discovery
A needle drawing up fluid from an unlabeled vial.
Cancer Vaccination as a Promising New Treatment Against Tumors
Shelby Bradford, PhD | Mar 15, 2024 | 10+ min read
Vaccination has beaten back infections for more than a century. Now, it may be the next big step in battling cancer.
bacteria inside a biofilm
How Bacterial Communities Divvy up Duties
Holly Barker, PhD | Jun 1, 2023 | 10+ min read
Biofilms are home to millions of microbes, but disrupting their interactions could produce more effective antibiotics.
September 2023 crossword image
What’s the Transmission?
Stella Zawistowski | Sep 8, 2023 | 2 min read
Put on your thinking cap, and take on this fun challenge.
microbiome drugs
How the Microbiome Influences Drug Action
Shawna Williams | Jul 15, 2019 | 10+ min read
Through their effects on metabolism and immunity, bacteria in the gut affect whether medications will be effective for a given patient.
Contributors
The Scientist | Jun 1, 2020 | 3 min read
Meet some of the people featured in the June 2020 issue of The Scientist.
Gene Jumped to All Three Domains of Life
Kerry Grens | Dec 1, 2014 | 1 min read
By horizontal gene transfer, an antibacterial gene family has dispersed to a plant, an insect, several fungi, and an archaeon.
Tumor microbiome composite
Could Cancer’s Microbiome Help Diagnose and Treat the Disease?
Jef Akst | Mar 14, 2022 | 10+ min read
A growing appreciation of the bacterial assemblages that live within tumors has researchers striving to understand and capitalize on their role.
Companies Seeking Solutions To Emerging Drug Resistance
Stephen Hoffert | Apr 12, 1998 | 10 min read
PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. Bacteria are back. Following the discovery and introduction into medicine of penicillin in 1941, intense research in microbiology produced a potent armament of antibiotics that all but eliminated a variety of infectious diseases. With this success, many large pharmaceutical companies scaled back research and development of new

Run a Search

ADVERTISEMENT